A Look At Ionis Pharmaceuticals (IONS) Valuation After Strong One Year Returns And Large Estimated DCF Upside

Simply Wall St.02-27

AdvertisementIonis Pharmaceuticals overview and recent share performance Ionis Pharmaceuticals (IONS) has drawn investor attention recently, with the share price closing at US$80.60 and showing mixed ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614836241?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-27 17:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614836241","market":"hk","top_or_hot":-1,"title":"A Look At Ionis Pharmaceuticals (IONS) Valuation After Strong One Year Returns And Large Estimated DCF Upside","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementIonis Pharmaceuticals overview and recent share performance Ionis Pharmaceuticals (IONS) has drawn investor attention recently, with the share price closing at US$80.60 and showing mixed ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/a-look-at-ionis-pharmaceuticals-ions-valuation-after-strong\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Ionis Pharmaceuticals (IONS) Valuation After Strong One Year Returns And Large Estimated DCF Upside</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Ionis Pharmaceuticals (IONS) Valuation After Strong One Year Returns And Large Estimated DCF Upside\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-27 17:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/a-look-at-ionis-pharmaceuticals-ions-valuation-after-strong><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementIonis Pharmaceuticals overview and recent share performance Ionis Pharmaceuticals (IONS) has drawn investor attention recently, with the share price closing at US$80.60 and showing mixed ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/a-look-at-ionis-pharmaceuticals-ions-valuation-after-strong\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/a-look-at-ionis-pharmaceuticals-ions-valuation-after-strong","article_id":"2614836241","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/a-look-at-ionis-pharmaceuticals-ions-valuation-after-strong","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614836241","pubTimestamp":1772184950,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ionis Pharmaceuticals overview and recent share performance\nIonis Pharmaceuticals (IONS) has drawn investor attention recently, with the share price closing at US$80.60 and showing mixed returns over the past week, month, past 3 months, and year to date.\nOver the past year, total return is 157.10%. The past 3 years and 5 years show total returns of 125.08% and 57.21% respectively, providing context for how the stock has behaved across different holding periods.\nSee our latest analysis for...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"在一年强劲回报和预计DCF大幅上涨后审视Ionis Pharmaceuticals(IONS)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":1.5,"DCF":1.5},"content_text":"AdvertisementIonis Pharmaceuticals overview and recent share performance Ionis Pharmaceuticals (IONS) has drawn investor attention recently, with the share price closing at US$80.60 and showing mixed returns over the past week, month, past 3 months, and year to date. Over the past year, total return is 157.10%. The past 3 years and 5 years show total returns of 125.08% and 57.21% respectively, providing context for how the stock has behaved across different holding periods. See our latest analysis for Ionis Pharmaceuticals. Recent trading has been softer, with the 7 day share price return of 3.06% and 90 day share price return of 2.57% sitting in contrast to the very strong 1 year total shareholder return of 157.10%. This highlights momentum built over a longer horizon even as near term sentiment cools. If Ionis has you thinking about where growth or volatility might show up next in healthcare, it could be worth scanning our screener of 29 healthcare AI stocks as a starting list of ideas. With Ionis delivering a very large 1 year total return alongside ongoing losses of US$381 million and an indicated intrinsic discount of 63.71%, you have to ask: is this a fresh opportunity, or is future growth already priced in? Most Popular Narrative: 11.1% Undervalued The most followed narrative puts Ionis Pharmaceuticals' fair value at about $90.67, compared with the last close at $80.60. This frames a valuation gap that hinges on how its triglyceride and rare disease franchises evolve.  Ionis' growing stream of high-margin royalty and milestone revenues from partnerships (e.g. Biogen, AstraZeneca, Roche), as well as recent substantial out-licensing deals, provides both capital efficiency and financial resilience, helping shore up net margins and reducing risk as operating expenses scale with new launches.  Read the complete narrative. Curious what is driving that higher fair value? The narrative leans heavily on faster revenue growth, a sharp shift in profitability, and a future earnings multiple that sits well above typical biotech names. The exact mix of growth, margins, and required valuation is where the story really gets interesting. Result: Fair Value of $90.67 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that upside story could unravel if key late stage approvals slip or if broader severe hypertriglyceridemia pricing turns out to be weaker than current assumptions. Find out about the key risks to this Ionis Pharmaceuticals narrative. Another way to look at Ionis’ valuation The first narrative leans on a fair value of about $90.67, but our DCF model goes further, suggesting Ionis could be trading at a very large discount. The current $80.60 share price sits 63.7% below its future cash flow value estimate of $222.09. Which story feels more realistic to you? Look into how the SWS DCF model arrives at its fair value. IONS Discounted Cash Flow as at Feb 2026Next Steps If this mix of strong returns, losses and valuation gaps leaves you on the fence, it is worth acting now to review the underlying data and weigh the trade off between growth hopes and risk. To help with that, you can look directly at the balance of 2 key rewards and 1 important warning sign and decide how comfortable you are with the current setup. Looking for more investment ideas? If Ionis has sharpened your focus, do not stop here. The real edge comes from lining up a broader watchlist of opportunities tailored to your style.  Target value opportunities by reviewing our list of 54 high quality undervalued stocks that may offer more attractive price tags than their fundamentals suggest. Prioritise resilience by checking companies in the 80 resilient stocks with low risk scores that score well on stability and downside protection. Hunt for fresh potential by scanning the screener containing 24 high quality undiscovered gems that the wider market may not be paying attention to yet.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614836241","isCrawlerRequest":true}